ArticleEnvironment international2022
Early-pregnancy plasma per- and polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project Viva cohort.
Article in Environment international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Ultra-processed Food Intake During Pregnancy and its Impact on Maternal Diet Quality and Weight Change: A Systematic Review of Observational Studies.Current nutrition reports · 2024Pooled it
- Determinants of maternal and neonatal PFAS concentrations: a review.Environmental health : a global access science source · 2023Pooled it
- A two-step Bayesian clustering approach to relate PFAS mixture profiles and dietary patterns in early pregnancy.Environmental research · 2026Article
- Association between gestational PFAS exposure biomarkers and risk of preeclampsia in the ECHO Cohort.Environmental research · 2026Article
- PFAS exposure and reproductive dysfunction: implications for outcomes in assisted reproductive technologies.Frontiers in endocrinology · 2026Review
- Prenatal per- and polyfluoroalkyl substances and blood pressure trajectories in the New Hampshire Birth Cohort Study.International journal of hygiene and environmental health · 2025Article
- Individual and mixtures of PFAS during pregnancy are associated with maternal cardiometabolic outcomes during pregnancy.Environmental health : a global access science source · 2025Observational
- Health Impacts of Per- and Polyfluoroalkyl Substances (PFASs): A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Perfluoroalkyl substances and preterm birth.Journal of perinatology : official journal of the California Perinatal Association · 2025Article
- Early-life exposure to PCBs and PFAS exerts negative effects on the developing central nervous system.Journal of hazardous materials · 2025Review
- Per- and Polyfluoroalkyl Substances and Outcomes Related to Metabolic Syndrome: A Review of the Literature and Current Recommendations for Clinicians.American journal of lifestyle medicine · 2025Review
- Unveiling the Research Void: Exploring the Reproductive Effects of PFAS Compounds on Male Health.Advances in experimental medicine and biology · 2025Review
- Emerging PFAS contaminants PFNA and PFSA amplify epigenetic aging: sex- and age-stratified risks in an aging population.Frontiers in aging · 2025Article
- Per- and polyfluoroalkyl substances (PFAS) and hypertensive disorders of Pregnancy- integration of epidemiological and mechanistic evidence.Reproductive toxicology (Elmsford, N.Y.) · 2024Review
- Environmental chemical exposures and a machine learning-based model for predicting hypertension in NHANES 2003-2016.BMC cardiovascular disorders · 2024Article
- Review
- Article
- Development of a Phthalate Environmental Reproductive Health Literacy (PERHL) Scale.Environmental health perspectives · 2024Article
- First trimester plasma PER- AND Polyfluoroalkyl Substances (PFAS) and blood pressure trajectories across the second and third trimesters of pregnancyEnvironment international · 2024Article
- Associations of Serum Perfluoroalkyl Substances and Placental Human Chorionic Gonadotropin in Early Pregnancy, Measured in the UPSIDE Study in Rochester, New York.Environmental health perspectives · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundHypertensive disorders of pregnancy (HDP), defined here as hypertensive disorders with onset in pregnancy (i.e., gestational hypertension, preeclampsia, and preeclampsia superimposed on chronic hypertension), affect up to 10% of pregnancies in the United States and are associated with substantial maternal and neonatal morbidity and mortality. Per- and polyfluoroalkyl substances (PFAS) are associated with adverse cardiometabolic outcomes during pregnancy, but associations between PFAS and HDP are inconsistent and joint effects of PFAS mixtures have not been evaluated.
methodsWe studied 1,558 pregnant individuals from the Project Viva cohort, recruited during 1999-2002. We quantified concentrations of eight PFAS in plasma samples (median 9.7 weeks of gestation). Using clinical records, we calculated trimester-specific mean systolic (SBP) and diastolic (DBP) blood pressure and categorized HDP status [no HDP (normotensive & chronic hypertension), gestational hypertension, preeclampsia]. We estimated associations of individual PFAS with HDP using multinomial logistic regression and estimated associations with blood pressure using linear regression. We used Bayesian kernel machine regression (BKMR) and quantile g-computation to assess joint effects of the PFAS mixture on HDP and blood pressure measures.
resultsFour percent of participants developed preeclampsia and 7% developed gestational hypertension. We observed higher odds of gestational hypertension, but not preeclampsia, per doubling of perfluorooctanoate (PFOA) [OR = 1.51 (95% confidence interval: 1.12, 2.03)], perfluorooctane sulfonate (PFOS) [OR = 1.38 (1.04, 1.82)], and perfluorohexane sulfonate [OR = 1.28 (1.06, 1.54)] concentrations. We observed higher mean DBP per doubling of PFOA [2nd trimester (T2): 0.39 mmHg (-0.01, 0.78); 3rd trimester (T3): 0.56 mmHg (0.14, 0.98)] and PFOS [T2: 0.46 mmHg (0.11, 0.82); T3: 0.43 mmHg (0.05, 0.80)]. The PFAS mixture was positively associated with odds of gestational hypertension [75th vs. 50th percentile: OR = 1.14 (95% credible interval:1.03, 1.25), BKMR] and mean DBP [T2 = 0.17 mmHg (-0.06, 0.40); T3 = 0.22 mmHg (-0.03, 0.48), BKMR].
conclusionsThese findings suggest that exposure to certain PFAS may increase the odds of gestational hypertension during pregnancy, with potential implications for subsequent maternal and child health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.